Atalanta Therapeutics Funded $110M for Neurodegenerative Diseases New Treatment Option


Atalanta Therapeutics based in Boston, MA. Provider of biotechnology principles to create therapeutics for neurodegenerative diseases.

Atalanta Therapeutics was funded $110 million in Series A financing. F-Prime Capital provided the investment exclusively. Atalanta started meaningful collaborations with Biogen (Nasdaq: BIIB) and Genentech, a Roche Group member.

Atalanta founded to address the significant constraint for today’s RNAi therapeutics: the struggle of achieving distribution, ultimately the brain and spinal cord. Atalanta’s proprietary technology, named branched siRNA, licensed from the University of Massachusetts Medical School, based on over 30 years of research in RNA biology and its clinical applications.

Being part of Biogen’s strategic collaboration, Atalanta will develop RNAi therapeutics for multiple targets, including HTT, to treat Huntington’s disease and added unnamed CNS targets. Atalanta will be qualified to receive development and milestone payments on these programs and royalty payments on any producing products.

The strategic collaboration with Genentech entails developing RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.

Alicia Secor, the President, and CEO of Atalanta, said the launch of Atalanta Therapeutics marks a hopeful new era for treating neurodegenerative diseases with several or no existing treatments. Patients, their caregivers, and society more commonly have an urgent need for improved therapies. Atalanta’s branched siRNA principles offer the promise to potentially leverage RNAi procedures in the central nervous system, starting a whole new class of diseases to RNAi intervention. It delights them to deploy this exciting technology with the end goal of delivering effective new therapies to patients.

Stacie Weninger, Ph.D., the President of F-Prime Biomedical Research Initiative (FBRI), said Atalanta’s founders, and strong preclinical data-position it for success. F-Prime is excited to included at this early stage of the company. She is looking forward to working collaboratively with Atalanta’s directors and management to improve our shared mission of pioneering new medication options for recalcitrant neurodegenerative diseases.

By: K. Tagura

Author statement: is the leading platform for accredited investors network worldwide. We monitor and provide updates on important funding events. Angel Investors and Venture Funding can be a key growth for a startup or existing business. Whether it is a first, second or third round financing having a strategic alliance with an Angel Investor or Venture Capital financing can propel a business to the next level and give the competitive edge.